CellSource Co., Ltd. (JP:4880) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CellSource Co., Ltd. will commence consolidated financial reporting starting from the fiscal year ending October 31, 2025, following the establishment of its subsidiary, Hybrid Medical Co., Ltd. The company has released its financial forecasts, projecting net sales of 4,501 million yen and a profit of 255 million yen for the upcoming fiscal year. These forecasts include the anticipated performance of Hybrid Medical.
For further insights into JP:4880 stock, check out TipRanks’ Stock Analysis page.